Title:Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Volume: 2
Issue: 12
Author(s): Vikas Pandey, Indu Lata Kanwar, Tanweer Haider, Vishal Gour, Monika Vishwakarma, Avijit Kumar Bakshi, Ravishankar Yadav and Vandana Soni*
Affiliation:
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh,India
Keywords:
ACE-2, COVID-19, SARS-CoV-2, TMPRSS2, Furin, ligand.
Abstract: The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-
-2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on
patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the coreceptor
for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to reduce
SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coronavirus
disease 2019 (COVID-19) infection has been known and the experts have started working
on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of
spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role
in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human
body causing asymptomatic pneumonia and severe of which is leading to death. As no specific
method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with
COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneumonia.
